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Abstract: Rapid in silico selection of target focused libraries from commercial repositories 
is an attractive and cost effective approach. If structures of active compounds are available 
rapid 2D similarity search can be performed on multimillion compound databases but the 
generated library requires further focusing by various 2D/3D chemoinformatics tools. We 
report here a combination of the 2D approach with a ligand-based 3D method (Screen3D) 
which applies flexible matching to align reference and target compounds in a dynamic 
manner and thus to assess their structural and conformational similarity. In the first case 
study we compared the 2D and 3D similarity scores on an existing dataset derived from the 
biological evaluation of a PDE5 focused library. Based on the obtained similarity metrices 
a fusion score was proposed. The fusion score was applied to refine the 2D similarity 
search in a second case study where we aimed at selecting and evaluating a PDE4B 
focused library. The application of this fused 2D/3D similarity measure led to an increase 
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of the hit rate from 8.5% (1st round, 47% inhibition at 10 µM) to 28.5% (2nd round at 50% 
inhibition at 10 µM) and the best two hits had 53 nM inhibitory activities. 
Keywords: 2D similarity; 3D similarity; ligand-based virtual screening; focused library; 
phosphodiesterase 4; phosphodiesterase 5; flexible alignment 
 
1. Introduction 
In the recent years we have witnessed an explosion in the number of compounds available for 
biological screening. For example, the ZINC database contains approximately 30 million molecules 
that are commercially available from various sources [1]. Furthermore, several databases provide 
access to biological activity data for small molecules that can serve as input data for model building 
and virtual screening. For example, PubChem [2] contains 119,958,113 reported compounds together 
with 717,473 bioassay counts; ChEMBL [3] collects 1,292,300 compounds with 11,000,000 activities 
for 9000 targets from 45,000 publications; Binding_DB (2013) [4] reports 773,900 compounds with 
1,010,714 binding data for 6910 protein targets as public databases. Commercial databases that 
monitor the progress of drug candidates are Pharmaprojects [5], with searchable profiles for over 
50,000 drugs and drug candidates; Integrity database [6] which is a multidisciplinary database 
supporting the drug research and development. Such large data collections could be exploited in  
in silico screening particularly if limited biological screening capacity is available for researchers. 
Furthermore, in many cases virtual screening and in vitro HTS are used as complementary tools [7]. 
Random screening of a discovery library often results in a poor hit rate (≤0.1%) [8] while the hit 
rate of in silico focused libraries could reach 1%. Furthermore, by means of the use of focused libraries 
the synthesis, repository management and screening costs could be reduced [9]. Up to present various 
ligand-based (LBVS) and structure-based virtual screening (SBVS) methods [10] have been reported 
for selecting focused libraries from compounds repositories [11]. 
Even though computational efficiency has improved significantly in the recent years, more reliable 
scoring and tedious post-processing is required in structure-based VS methods. Therefore, ligand—based 
VS approaches have become popular including: pharmacophore models, neural networks, discrimination 
of known active and known inactive molecules etc. Ligand-based similarity search methods using 2D 
fingerprints are very effective and widely used approaches that apply the old similarity principle: 
“structurally similar molecules are likely to have similar properties” [12,13]. 
2D similarity search is certainly the method of choice when numerous active reference compounds 
and multimillion compound databases are available [14]. Similarity is generally expressed in  
Tanimoto coefficients [15]. 
The search results could be focused by property–based filtering taking into consideration of the 
physico-chemical parameter space of the reference compounds. On the other hand it is claimed that 
“similarity-based compound ranking is an insufficient indicator of the biological activity” [9]. 
3D target or ligand-based approaches could help for refining the 2D virtual screening results and 
increasing further the hit rate. For example 2D similarity search results could be ranked according to 
docking scores if proper 3D models are available. One of the major challenges of docking is protein 
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flexibility [16] and the adaption of the proper conformation is a critical element in ligand binding. 
Either multiple static binding conformations can be considered to overcome the problem or  
docking should allow molecular dynamics simulations [17]. The situation is more complicated, if 
water molecules participate in the binding. The above methods can be also target specific and these 
methods do not work effectively with all protein types. 
All these arguments highlight the fact why 2D similarity methods still enjoy high popularity and 
also explain the high demand for rapid, innovative solutions in terms of 3D ligand–based methods. 
Ligand-based approaches do not take the target structure directly into account. These techniques are 
based on the assumption that compounds with similar topology have similar biological activities. 
The possible binding features of small molecules can be assessed by their conformational flexibility 
and shape. The conformations are created on-the-fly, and the statistical representation of all possible 
conformations could be viewed as a 3D structure. During flexible alignment (such as applied in 
Screen3D software) dynamic 3D structures can be compared and their similarity or dissimilarity can be 
determined and expressed in 3D similarity measures. Flexible alignment methods do not require a  
pre-defined set of initial conformers to sample the conformational space of the molecules. During the 
alignment procedure atom-type information would be capable of generating alignments where patterns 
with similar binding character are oriented in a similar fashion in the known active and the candidate 
structures. This provides a more realistic picture of the potential bioactive similarity of the molecules. 
In the present study our objective was to evaluate the utility of the 3D flexible alignment approach 
in similarity-based focused library generation. We have chosen two important members of the 
phosphodiesterase family, PDE5 and PDE4 as biological targets for this study. Phosphodiesterase 
(PDE) enzymes are implicated in various physiological processes mediated by cAMP or cGMP. PDE 
inhibitors, which block the degradation of the above second messengers regulated by the enzymes, are 
potential therapeutic agents in various pulmonary, cardiovascular diseases as well as in CNS disorders. 
PDE5 inhibitors are used in the treatment of erectile dysfunction, as the first effective oral medication, 
as well as for the therapy of pulmonary hypertension. 
PDE4 inhibitors are known to possess long-term memory-improving, neuroprotective and particularly 
anti-inflammatory effects that are useful in the therapy of chronic obstructive pulmonary disease 
(COPD), asthma and rheumatoid arthritis [18]. 
In a previous screening campaign we generated a PDE5 focused library where the compounds were 
selected exclusively by 2D similarity search methods and screened in in vitro assays [19]. The dataset 
generated during the study served as an ideal starting point to analyze and correlate 2D and 3D 
similarities as well as giving us a hint how to combine (fuse) the 2D and 3D similarity measures in 
further applications, namely, selecting PDE4 inhibitors from large vendor compound libraries. 
In the present paper we report: (a) 2D/3D similarity analysis of a previous phosphodiesterase 5 (PDE5) 
screening campaign; (b) combination of 2D and 3D similarity search for selecting a hit validation 
focused library in a PDE4 screening campaign. Similarities are expressed in 2D (T2D) and 3D (T3D) 
Tanimoto coeffiecients. As starting points we collected 44 structurally different active PDE5 inhibitors 
and 44 PDE4 inhibitors representing from literature and available databases (see Supplementary Material). 
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2. Results and Discussion 
2.1. Case Study 1: 2D/3D Analysis of Available Data from PDE5 Screening 
First round screening: The 2D selection strategy for the generation of a PDE5 focused library 
generation was reported earlier [19]. We used such dataset to investigate the correlation between the 
2D and 3D similarities and learn how to apply flexible alignment (Screen3D software) more efficiently 
in further in silico screening campaigns. We involved five hit compounds (IC50 < 10 µM, Table 1) in 
our analysis reported that were selected based on the structure of three known PDE5 inhibitors as 
reference or seed compounds (#13, #18, #44, see Table 1—column “Seeds”). 
Table 1. First round screening hits as potential PDE5 inhibitors with T2D and T3D values. 
ID Hits IC50 (µM) T2D T3D Seeds Seed ID 
1 3.65 0.63 0.47 
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HN
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O
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HNHO
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O
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The 3D similarities were calculated by the Screen3D software and correlated with the 2D (T2D) 
values. While the T2D values were over 0.60 (that was the criteria of the selection), the 3D Tanimoto 
scores (T3D) were much lower and were often just above 0.3. The significant differences in the 2D 
(T2D > 0.60), and 3D Tanimoto scores (T3D > 0.3) revealed that even though the compounds  
selected by 2D methods had similar molecular architectures, they are rather different in terms of  
shape and conformational flexibility. Such 3D dissimilarity is assumed to represent much different 
binding characteristics. 
Figure 1a shows the scatter plot of correlating the 2D and 3D similarity scores of all the measured 
compounds (41, active and not active) derived from the three reference compounds (#13, #18, #44) in 
the first screening round. Since the five hits had T3D values > 0.3 we indicated such a value on  
Figure 1a. In Figure 1b PDE5 inhibition % values were correlated with the T3D values. Interestingly, 
the T3D values of the best hits were over 0.3 although together with lots of false positives (45% of all 
compounds measured). As an inhibition cut-off value, we applied 57% at 10 µM concentration (this 
inhibition % value provided a reasonable number compounds for concentration dependency studies). 
Figure 1. Scatter plot of all the measured compounds (41, active and not active) derived 
from the 3 seeds (#13, #18, #44) correlating the T2D and T3D similarity scores (a); and 
correlating the IC50 values and T3D values (b). 
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The first round selection and screening led to the conclusion that T3D = 0.3 might have been a 
useful cut-off value. Based on the structure of the first round screening hits, 104 compounds were 
selected for the 2nd round (hit validation) screening by 2D methods as reported earlier [19]. The 
selection criterion was T2D ≥ 0.8. Now the 3D similarities of the selected set to the corresponding first 
round hit compounds were calculated and the T3D values were between 0.35 and 0.95. The 2D/3D 
correlation is shown in Figure 2. There is a certain trend that with increasing 2D values the 3D values 
are also increasing but in a lower extent. Interestingly, the majority of the compounds have T3D values 
above 0.6. 
Figure 2. Correlation between T2D and T3D values of the compounds (104) selected for 
the second round screening. 
 
Most of the second round hit compounds (13 out of 20) derived from two PDE5 reference 
compounds (#18, #44). We analyzed separately these two series of compounds. The 3D similarities 
between the 2nd round (IC50 ≤ 2 µM) and the first round hits as well as the reference compounds were 
displayed in Figures 3 and 4. Figure 3 shows the IC50 values of compounds derived from #2 and #44 
(upper value); the T3D values to #2 (middle) and the T3D values to the reference compounds #44 
(lower value). 
Similarly, Figure 4 shows the IC50 values of compounds derived from #3 and #18 (upper value); the 
T3D values to #3 (middle) and the T3D values to the reference compounds #18 (lower value). For 
those hit compounds the 2D similarities were above 0.8 by definition, 3D similarities to the 
corresponding first round hits were between 0.42 and 0.91, while to the corresponding original seeds 
varied between 0.22 and 0.34, respectively. Combining the T2D/T3D similarities into a single fusion 
score we found that T2D + T3D is ranging between 1.22 (0.8 + 0.42) and 1.71 (0.8 + 0.91) for the 
second round screening. 
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Figure 3. Hits derived from #44 seed with the T3D similarities to the first round hit and 
seed (reference compound)—Series #2. 
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Figure 4. Hits derived from #18 seed with the T3D similarities to the first round hit and 
seed (reference compound)—Series #3. 
0.75 µM
0.48
0.23
0.81 µM
0.527
0.232
0.82 µM
0.57
0.342
1.15 µM
0.691
0.339
0.81 µM
0.473
0.296
7.24 µM
0.31
#3
0.26 µM
0.498
0.217
0.1 µM
0.553
0.245
#18
 
Molecules 2014, 19 7015 
 
 
Analyzing the second round hit compounds (13) derived from #2 and #3 first round hits (Series #2 
and Series #3 compounds) we got different results. While analogues in Series #2 have high T3D scores 
(between 0.7 and 0.9), those compounds that derive from Series #3 show significantly lower 3D 
similarity values (between 0.42 and 0.63) (Figures 3 and 4) (note: 2D similarity is over 0.8 for all the 
compounds by definition). This clearly shows that such analogs could have significantly different 
binding characteristics than the first round hit they derive from. The significant improvement of the 
inhibitory activities confirms such findings (from 7.29 µM to 0.1 µM). We could also conclude  
that in Series #3 if the saturated ring (cyclohexyl) is replaced with aromatic moieties the activity is 
significantly increases. 
Looking at the T3D values of these second round hits correlated with the original reference 
compounds (seeds) in Figures 3 and 4 we could find again a major difference between the two series of 
compounds (Series #2 and #3). While analogues derived from #18 have higher T3D scores (between 
0.31 and 0.39), those compounds that were derived from #3 show lower 3D similarity values (between 
0.21 and 0.34). 
Based on the above analysis we could conclude that T3D values are much more sensitive measures 
than their T2D counterparts and they reflect important structural features (e.g., conformational 
flexibility) that strongly depend on the structure. Interestingly, the T2D and T3D sensitivity is also 
structure dependent. We could also state that T3D = 0.3 would be a good cut-off value in the first 
round similarity selection and T3D = 0.5 or 0.6 in the second round (hit validation). Of course if we 
apply stricter filters the “focusing” would give probably a higher hit rate but some compounds 
(chemotypes) would have been lost. In summary, based on the above study we envisaged that 
combination of the 2D/3D similarity measures could have definite advantages in ligand-based  
virtual screening. 
2.2. Case Study 2: Application of Combined 2D/3D Similarity Selection in Generating of a PDE4 
Focused Library 
In this second case study we applied Screen3D in a real virtual screening situation to select PDE4 
inhibitor focused library, similarly from multi-million compound repositories.  
First we applied a similar 2D selection strategy as we reported for PDE5 [19]. In the second round 
(hit validation) library selection we used Screen3D in combination with the 2D approaches (Figure 5). 
The 2D similarity search in the first round was performed based on the structure of 44 known PDE4 
inhibitors (collected from the literature) on our five million compound vendor collection. We selected 
PDE4 inhibitors as seed compounds that have low nanomolar inhibitory activities plus we added some 
interesting chemotypes, where no activities were reported in order to increase the chemical space.  
The similarity search was followed by property space filtering, applying the calculated ranges  
of 6 physico-chemical parameters (LogP, Mwt, tPSA, HBD, HBA and rotational bonds) relevant  
to drug-likeness with equal weight. Finally, simple diversity selection reduced the library size  
from 1764 to 200. After visual inspection of the compound set we send an inquiry for 120 compounds, 
and the available compounds (105) were ordered. In vitro measurements at one single concentration 
resulted in nine compounds (>47% inhibition at 10 µM concentration), and those were selected for 
measuring the concentration dependency determining the IC50 values. As a result seven compounds 
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were considered as hits (IC50 ranges from 0.05 to 16 µM). The hit rate of the first round screening was 
6.6% (>47% inhibition) and the success rate was 2.8% if we consider the hits below 2 µM (IC50). 
Table 2 shows the first round screening results (note: 47% inhibition was chosen instead of 50% to 
involve more compounds into the IC50 determination). 
Figure 5. In silico selection scheme of the PDE4B focused library. 
 
The seven first round hit compounds served as seed compounds for the second round (hit 
validation) library selection. Based on the experience we gathered during the analysis of PDE5 
inhibitor library selection we decided to apply Screen3D as a filtering tool in combination with 2D 
similarity search at this stage. First we carried out a standard 2D similarity search since Screen3D 
could only handle a couple of thousand compounds rather than a couple of million. As a second step 
we calculated the 3D similarity values towards their corresponding first round hits for 1341 
compounds that were obtained after 2D similarity search (T2D > 0.65) and the property space filtering. 
The 3D similarity values towards their appropriate first round hits for 1341 compounds were 
calculated and their correlation to the 2D score is shown in Figure 6). We found a similar trend as with 
PDE5 the 3D Tanimoto coefficient ranged from 0.19 to 0.99 while the 2D cut-off value was 0.65.  
We recognized again a weak linear correlation between the 2D and 3D similarity measures (Figure 6). 
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Table 2. 7 hits obtained in the first screening round. 
ID Structure Inhibition IC50 µM T2D Seed_ ID Seed 
2 N
N N
O
O
F
0.92 0.053 0.66 38 
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CH3
O
O
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O
O
CH3
H3C
OH
 
5 
O
N
O
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CH3
N
N
CH3 0.71 1.97 0.7 42 N
N N
O
O
CH3
CH3
N CH3
O
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CH3
 
4 
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F
HN
O
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O
H3C
N
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F
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O
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N
H3C
O
O
H3C
CH3 O
 
Molecules 2014, 19 7018 
 
 
Figure 6. Correlation between the T2D and T3D values. 
 
Based on earlier findings a combination of T2D and T3D looks more appropriate for reducing the 
number of compounds for biological screening and implementing conformational information. There 
are various options to combine those two scores. First, the T2D and T3D scores can be weighed 
differently giving more emphasis on any of the approaches. Secondly, the fusion score can be either an 
aggregation or a fraction. 
There is an aggregation type of fusion score in 2D virtual screening which combines T2D similarity 
scores to more than one compound. In this approach first the similarity scores to “n” reference 
compounds are calculated for each compound within a medium sized compound library and then the 
“n” similarity measures obtained for each compound of the library are accumulated (“fused”) [20]. 
Furthermore, the cut-off values can also be debated. We propose a fusion score which treats the 
influence of T2D and T3D equally and aggregates the scores. A suitable cut-off value was proposed as 
T2D + T3D ≥ 1.5 based on the following considerations: 
(1) Since T2D was ≥ 0.65 (cut-off value) at such relatively lower 2D similarity level only those 
compounds would be in the selection where the T3D similarity is high (>0.85). (Note: In the 
PDE5 study we found that the fusion score was between 1.22 and 1.7 in the 2nd round screening. 
Since in that case the T2D cut-off value was 0.8 low T3D values were also acceptable). 
(2) Inversely, in the case of higher T2D values (max. 0.96) compounds could be selected even in 
the case of lower T3D values (min. 0.54). 
(3) Our preference to equal weight of T2D and T3D scores can be explained by the objective of the 
hit validation, which requires relatively close (2D) analogues. 
This combined cut-off value resulted in a relatively small number of compounds (from 1341 to 233) 
(Figure 7a) (nevertheless, 90 compounds were excluded that exceeded T3D = 0.65, due to the lower 
than 1.5 cumulative score). The representation of the compounds derived from the seven first round 
hits varied significantly showing that the T3D ranges and its distribution strongly depend on the 
chemotypes (see Table 3). For example analogues derived from #4 and #1 were recovered in  
the 233 set higher than 40% while other analogue groups were underrepresented (#3 and #6). This is 
partly due to the low T3D values (0.19 and 0.29 respectively). 
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Table 3. Distribution of the T3D values in the entire second round selection library and 
within the library having fusion score above 1.5. 
ID Structure 
Analogues in 
the 1341 Set 
Lowest 
T3D 
Analogues in 
the 233 Set 
Lowest 
T3D 
Percentage in 
the 233 Set 
2 
 
N
N N
O
O
F
155 0.24 30 0.69 19.35 
3 N
NN
N
H3C O
O
F
O
CH3
 
476 0.19 16 0.63 3.36 
5 
N
N
N
O
O
O
CH3
CH3
 
27 0.33 9 1.00 33.33 
4 
H3C
F
HN
O
N
S
H3C
O
 
13 0.28 6 0.72 46.15 
1 N
N N
N
HN
CH3
O
O
CH3
CH3
H3C
 
273 0.30 116 0.62 42.49 
6 N
CH3
O
H3C
O
CH3
O
 
117 0.29 12 0.70 10.26 
7 
N
N
O
O O
N
280 0.28 44 0.64 15.71 
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After the 2D/3D combination filtering, which resulted in 233 compounds, the library was  
reduced to 70 by diversity selection and this compound set was ordered. Unfortunately, only  
35 compounds were available; however, the obtained compound set reflected the distribution of  
the initial set of compounds (233). In vitro screening of the small focused library resulted in 10 hits 
(IC50= 0.053–3.2 µM, Table 4). In general the contribution of T2D is gradually increasing but 
fluctuating between 0.65 and 1, while T3D is decreasing from 1 to 0.6 among the compounds that have 
a fusion score of 1.5 (Figure 7b). 
Figure 7. (a) Selection of 233 compounds out of 1341 that have a fusion score ≥ 1.5;  
(b) Increasing and fluctuating contribution of the 2D Tanimoto coefficient to the fusion 
score between 0.65 and 1, while 3D Tanimoto decreasing from 1 to 0.6 among the compounds 
that have a fusion score 1.5. 
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Table 4. 10 hits obtained in the second screening round. 
ID Structure 
Inhibition at 
10 µM (%) 
IC50 (µM) T2D T3D Fusion Score T2D/T3D First Round Hit_ID
First Round 
Hits 
Chemo 
Type 
3 N
N N
O
O
FF
F
83 0.053 0.9 0.88 1.78 1.02 2 N
N N
O
O
F
 
A2 
5 N
N N
O
O
O
CH3
94 0.105 0.86 0.87 1.73 0.99 2 N
N N
O
O
F
 
A2 
4 N
N N
O
O
F
Cl
 
90 0.779 0.92 0.83 1.75 1.1 2 N
N N
O
O
F
A2 
6 
N
N
N
O
OF
O
CH3
88 1.1 0.89 0.82 1.71 1.09 2 N
N N
O
O
F
 
A2 
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Table 4. Cont. 
ID Structure Inhibition at 
10 µM (%) 
IC50 (µM) T2D T3D Fusion Score T2D/T3D First Round Hit_ID First Round Hits Chemo 
Type 
8 N
N N
O
O
F
F
86 1.4 0.81 0.69 1.50 1.18 2 N
N N
O
O
F
 
A2 
7 
N
N
N
O
OCl
O
CH3
89 3.0 0.84 0.78 1.62 1.08 2 N
N N
O
O
F
 
A2 
1 N
N
N N
N
CH3
H3C
O
O
CH3
CH3
CH2
H2C
 
51 1.7 0.85 0.69 1.54 1.24 1 N
N
HN N
N
CH3
H3C
O
O
CH3
CH3
 
B1 
2 
N
N
N N
N
CH3
H3C
O
O
CH3
CH3
 
61 1.4 0.84 0.67 1.51 1.25 1 N
N
HN N
N
CH3
H3C
O
O
CH3
CH3
 
B1 
9 N
N
N
N
N
H3C
CH3
H3C
CH3H3C
O
O
CH3
 
62 3.2 0.85 0.65 1.5 1.31 1 N
N
HN N
N
CH3
H3C
O
O
CH3
CH3
B1 
10 
N
N
O
O
Cl
CH2
O
 
62 2.4 0.88 0.64 1.52 1.38 7 
N
N
O
OO
N
A11 
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The hit rate of the 2nd round screening was 28.5% (>50% inhibition, at 10 µM), while 10% hit rate was 
calculated if only those compounds were considered that had an IC50 values < 2 µM (seven compounds). 
We also analyzed the correlation of the hits. The T2D/T3D correlation and fusion score analysis 
applied on the 10 second round hits revealed that six out of the 10 hits have a fusion score around 1.5, 
which is close to the cut-off value (Figure 8). It means that T3D values are apparently low in those 
cases while T2D is around 0.8. This finding suggests that the fusion score should be decreased to 1.3, 
which would allow the involvement of more compounds with lower T3D values. On the other hand it 
looks that the biological activity correlates well with the T3D values (which is actually more sensitive 
in nature). 
Figure 8. T2D/T3D and fusion score analysis of the 10 second round hits. 
 
2.2.1. Structural Analysis of the Hits 
Looking at the structural relationship of the first round hits and their seeds we could identify several 
pairs where the core structure is retained (3 → 13, 5 → 42, 4 → 29, 6 → 14, 7 → 24, Table 3) and 
others, where we could recognize scaffold hopping (1 → 13, 2 → 38) (Figure 9). In the second round 
screening only three chemotypes were represented in the selected seven compounds which derived 
from hit #1, #2 and #7 (Table 4). We searched PubChem for such chemotypes, whether they have 
already been reported as potential PDE inhibitors. 
We found an analogue for hit #2 (1st round, 53 nM) what we might have missed during the search 
for reference compounds (Figure 10, same chemotype with different substitution pattern), however, the 
reported activity of such analogue was only 950 nM) [21]. 
Furthermore, for chemotypes that represented in hits #1 (1st round, 11 µM) and #2 (2nd round,  
1.4 µM) we did not find any biological data in PubChem, the closest analogue exhibited biological 
activity as an adenosine A(1) and A(2A) antagonistic effect [22]. 
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Figure 9. Hit evolution involving scaffold hopping. The hit evolution sequence of two 
second round hit compounds that involved scaffold hopping. #2 (2nd) → #1 (1st) → #13 
(seed) (upper scheme) and #3 (2nd) → #2 (1st) → #38 (seed) (lower scheme). 
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Figure 10. PubChem listed compound as analogue of the hit #3. 
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2.2.2. PDE4B Selectivity 
Recently our attention has turned to respiratory diseases mediated by PDEs. While PDE4B  
subtype is predominant in inflammatory cell regulation PDE4D inhibition has primarily CNS effects. 
Therefore, PDE4B is a therapeutic target for airway inflammatory diseases such as COPD while 4D is 
an anti-target and often responsible for side-effects, therefore certain selectivity for 4B against 4D 
would have additional values in the therapy [23]. Furthermore, multitarget therapies have become 
widely accepted in the recent years. Dual inhibition with either PDE3 or 7 and sometimes additional 
PDE5 inhibition had beneficial effects. 
Although we did not discriminate PDE subtypes in the selection of the seed inhibitors thus we have 
not target selectivity in the study we decided to screen our hits compounds on the available PDE panel 
in order to determine the activity profile of our PDE4B hit compounds. Table 5 summarizes the results. 
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Table 5. The activity profile of 11 selected hit compounds (n.i. denotes no inhibition). 
ID Structure 
PDE4B PDE4B PDE4D PDE5 PDE2 PDE3 PDE7 PDE8 PDE9 PDE10A PDE11 
inh.% (10 µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) 
3 
N
N
N
O
O
FF
F
83 0.053 35.1 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
5 
N
N
N
O
O
O
94 0.105 1.12 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
4 
N
N
N
O
O
Cl
F
90 0.779 7.8 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
6 
N
N
N
O
O
F
O
88 1.1 10.7 n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
8 
N N
N
O
O
F
F
86 1.4 7.5 5.8 n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
7 
N
N
O
CH3
Cl O
O 89 3.0 8 60 n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
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Table 5. Cont. 
ID Structure 
PDE4B PDE4B PDE4D PDE5 PDE2 PDE3 PDE7 PDE8 PDE9 PDE10A PDE11 
inh.% (10 µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) 
2 N
NN
N
N
O
O
61 1.4 24 n.i. n.i. n.i. n.i. n.i. n.i. 40.8 n.i. 
1 N
NN
N
N
O
O 51 1.7 41 11.7 n.i. n.i. n.i. n.i. n.i. 2.4 40 
9 
N
NN
N
N
O
O
62 3.2 n.i. 12.5 n.i. n.i. n.i. n.i. n.i. 0.6 n.i. 
11 N
NN
N
N
O
O
Cl
62 4.7 350 n.i. n.i. n.i. n.i. n.i. n.i. 8.5 n.i. 
10 
N
N
O
O O
Cl
62 2.4 13.5 32.8 n.i. n.i. n.i. n.i. n.i. n.i. n.i. 
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We found that most of the hit compounds showed some selectivity towards PDE4B and in some 
cases the selectivity was surprisingly high (50–80 fold) over PDE4D. Some of the hits inhibited PDE5 
at low concentration which could be useful in the therapy while PDE10 inhibition could be avoided, 
since that target is more implicated in CNS disorders. The observed selectivity was further investigated 
by in silico methods in order to get into structural insights (discussed later). 
2.2.3. Structural Analysis of the Hit Compounds 
Since the X-ray structure of most PDEs is already known we carried out docking calculations on  
the best hits having an imidazo[1,2-g]purine-2,4-dione ring system (#2 hit—2nd round) and substituted 
1H-purine-2,6-dione (#3 hit—2nd round). First we docked #2 and #3 into the PDE4B target structure 
in order to get information about the probable binding mode using the Glide XP program of the 
Schrodinger Suite 2013-3 package [24]. We used the 3G45 [25] structure from the PDB [26,27] 
database. The best scoring pose of ligand #2 and #3 (2nd round hits) can be seen in Figures 11 and 12, 
respectively. Figures were created using the PyMOL [28] software. 
Figure 11. The structure of the Glide XP calculated PDE4B—#2 (2nd round hit) complex. 
Ligand carbon atoms are marked in yellow, while the nearest interacting protein residue 
side chains are shown in cyan color. The yellow dotted lines represent inter-molecular 
hydrogen bonds. 
 
In order to demonstrate the most important interactions between the ligands and the binding site we 
created 2D structure diagrams of the ligand and its interacting residues using the PoseView [29] 
software. These diagrams can be seen in Figures 13 and 14. 
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Figure 12. The structure of the Glide XP calculated PDE4B—#3 (2nd round hit) complex. 
Ligand carbon atoms are marked in yellow, while the nearest interacting protein residue 
side chains are shown in cyan color. The yellow dotted lines represent inter-molecular 
hydrogen bonds. 
 
Figure 13. Diagram of the most important interactions in the Glide XP calculated 
PDE4B—#2 (2nd round hit) complex identified by PoseView. Black dashed lines represent 
hydrogen bonds, green solid lines represent hydrophobic interactions and green dashed 
lines represent aromatic interactions. 
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Figure 14. Diagram of the most important interactions in the Glide XP calculated 
PDE4B—#3 (2nd round hit) complex identified by PoseView. Black dashed lines represent 
hydrogen bonds, green solid lines represent hydrophobic interactions and green dashed 
lines represent aromatic interactions. 
 
In the case of ligand #3 in Figure 14 we can see that the Tyr274 residue (according to the PDB 
numbering), belonging to the UCR2 domain of PDE4B, does not only contribute to the ligand binding 
through aromatic interaction but it also participates in the formation of a hydrogen bond. We docked 
ligand #3 (2nd round hit) into the 3G4G PDE4D structure. The PoseView diagram of this complex can 
be seen in Figure 15. The equivalent of the Tyr274 is the Phe196 residue in the PDE4D structure, which 
cannot participate in the formation of a hydrogen bond. This additional H-bond might explain the high 
PDE4B specificity of ligand #3 (2nd round hit, IC50, PDE4B = 0.053 µM, IC50, PDE4B = 35.1 µM). 
In order to investigate the PDE subtype specificity we performed MM-GBSA binding energy 
prediction calculations on some hits. We used the X-ray structure of the longest available versions  
of PDE4B, PDE4D, PDE5A and PDE10A found in the PDB, namely the 3G45 [25], 3G4G [25],  
2H42 [30] and 3HR1 [31] structure, respectively. The results of such calculations usually show good 
correlation with experimental results [32] (see Table 5 vs. Table 6) and the calculated binding energies 
obtained with the same receptor structure can be used for comparison to experimental binding affinities. 
In order to get precise result Induced Fit Docking (IFD) calculations [33] were done in the case of  
2 ligands using all receptor structures. During this procedure the binding site residues are allowed to 
change conformation in order to adapt to the ligand structure. In the best scoring complex  
structures MM-GBSA binding energy calculations were performed using the Prime module of the 
Schrödinger Suite. 
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Figure 15. Diagram of the most important interactions in the Glide XP calculated 
PDE4D—#3 (2nd round hit) complex identified by PoseView. Black dashed lines represent 
hydrogen bonds, green solid lines represent hydrophobic interactions and green dashed 
lines represent aromatic interactions. 
 
The ranking based on the predicted binding energies shows nice correlation to the experimental IC50 
values of these ligands. In all cases where no inhibition was detected experimentally the calculated 
ΔGbind values are worse than −70 kcal/mol, these cases are marked in italics (Table 6). The binding 
energy and the inhibition data are particularly in good agreement for #11 since this compound also 
inhibits PDE10A at relatively low concentration (IC50 = 8.5 nM) beside PDE4B. 
Table 6. ΔGbind energies obtained from MM-GBSA calculation for various PDE variants. 
ΔGbind (kcal/mol) 
N
N
N
O
O
FF
F
 
#3 in the 2nd round 
N
O
N
NN
Cl
N
O
 
#11 in the 2nd round 
PDE4B (3G45) −113.367 −86.648 
PDE4D (3G4G) −103.014 −85.913 
PDE5A (2H42) −68.768 −67.397 
PDE10A (3HR1) −69.916 −92.082 
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2.2.4. Investigation of Structure- Activity Relationships by 3D Modeling 
For the most common chemotype in our study (1H-purine-2,6-diones) we analyzed the various 
substitutions around the core in order to draw some conclusion regarding the structure—activity 
relationships. It is obvious that meta-substituted benzyls at R1 position are favored together with 
unsubstituted phenyl groups at R2 (Figure 16). 
Figure 16. Preliminary structure-activity relationships of the most common chemotype of 
the 2nd round screening. 
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In order to model the observed structure activity relationships we performed MM-GBSA ΔGbind 
calculations using the Prime module of the Schrödinger Suite on a series of ligands which share the 
same scaffold (#3, #5, #4, #6, #8, #7—Table 7) using the 3G45 PDB receptor structure. The calculated 
ΔGbind values cannot be compared directly to the IC50 values, only to the pIC50 = −log (IC50) values. 
There is a nice correlation between the predicted binding energies and the pIC50 values, the correlation 
coefficient R2 = 0.49. 
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Table 7. ΔGbind values obtained from MM-GBSA calculation and experimental IC50/pIC50 
values for ligands with the same scaffold. 
ID Structure 
PDE4B PDE4B 
pIC50 
ΔGbind 
(kcal/mol) inh.% (10 µM) IC50 (µM) 
3 
N
N
N
O
O
FF
F
 
83 0.053 7.2757 −113.367 
5 
N
N
N
O
O
O
 
94 0.105 6.9788 −100.861 
4 
N
N
N
O
O
Cl
F  
90 0.779 6.1085 −111.562 
6 
N
N
N
O
O
F
O  
88 1.1 5.9586 −84.814 
8 N
NN
O
O
F
F  
86 1.4 5.8539 −80.407 
7 
N
NN
O
H3C
ClO
O
 
89 3 5.5229 −89.880 
We calculated the binding energies with the MM-GBSA method for the #3 hit molecule and the  
co-crystallized ligand as a reference using the 3G45 PDB structure. The #3 hit molecule has more 
preferable predicted binding energy (ΔGbindMM−GBSA = −113.367 kcal/mol) than the crystal ligand 
(ΔGbindMM−GBSA = −101.679 kcal/mol—8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline, PDE4B 
inhibition = 4.4 nM). Then we removed the UCR2 domain from the receptor structure and we repeated 
the calculation for ligand #3 and the crystal ligand and we got −76.045 and −80.120 kcal/mol, 
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respectively. These calculations indicate that the UCR2 domain is required for high affinity binding of 
these ligands, like in the case of rolipram [34]. 
3. Experimental 
3.1. Computational Methods 
3.1.1. 2D Similarity Search 
For 2D similarity search, we applied fingerprints as implemented into InstJChem software 
(ChemAxon Ltd., Budapest, Hungary) [35]. A compound was defined as an analogue if the  
Tanimoto coefficient (Tc) [36] to any reference compound was >0.65. The searchable drug-like 
chemical space was composed by existing/real compounds: non-exclusive commercial libraries were 
available from the actual edition of the top vendor databases (~5 million compounds): ChemBridge, 
ChemDiv, Asinex, Enamine, IfLab, UkrOrg, AMRI, Specs, Maybridge, Interbioscreen [37–46]. The 
reference/active chemical space was defined by collecting known PDE inhibitors (“seeds”) from 
available literature, PubChem [2] and various commercial (annotated) databases [5,6] including 
compounds with biological activity data from preclinical to clinical candidates and preferably with 
efficacies below 1 µM. As a second step the structures were clustered to major chemotypes and 
reviewed to remove the redundant structures. 
3.1.2. Calculation of the Physico-chemical Parameters and Property-based Filtering 
Physicochemical descriptors are used in property–based drug design and can be used to refine  
the 2D similarity search [47,48]. The primary physicochemical parameters are Molecular weight, Log P, 
H-bond donors, H-bond acceptors, H-bond donors, Rotatable bonds, Topological polar surface area. 
The first 4 parameters are included in the Lipinski’s Rule of 5 [49], while the additional 2 are among 
the Veber rules [50]. Those rules propose certain general limits for library filtering, which correspond 
to a parameter “window” favorable for oral absorption. Target-specific parameter space (different from 
the general Lipinski and Veber rules) defined by the active reference compounds is practical for library 
filtering since various target families have a distinct property range as conclude by Morphy et al. [51] 
in his recent study. 
The physico-chemical parameters (Mwt, LogP, H-bond donors/acceptors, rotatable bonds and 
topological polar surface area) were calculated by the calculation suit of InstJChem (ChemAxon Ltd.). 
3.1.3. 3D Ligand-Based Similarity Search for Ranking and Filtering of Focused Libraries 
For 3D ligand-based similarity search we applied flexible alignment through the Match algorithm of 
the Screen3D software (Screen3D 5.1, ChemAxon Ltd. Budapest). Practically Match algorithm applies 
first a marking step of the specific atoms with predefined atom types and pharmacophore rules, which 
are followed by the calculations of minimum and maximum possible intramolecular distances between 
every atom-atom pair during the high-throughput continual conformational scan. Intramolecular 
distances are collected for the formation of distance range histograms. A single histogram represents 
the cumulative distance range distribution of the given type of atoms from the selected atoms. Then the 
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distance ranges are coded in histograms and two histograms can be compared using histogram 
Tanimoto, where each histogram has two identifiers, an atom that is assigned to and an atom type. 
Finally, an atomic similarity score is calculated between a single atom of the query (a) and that of the 
target (b) using their histograms [52]. 
3.1.4. Diversity Selection 
In order to better/further reduce the combined selection to a reasonable and affordable library size, 
the above methods were complemented with diversity selection. Diversity selection was carried out by 
Similarity Manager (CompuDrug Int., Sedona, AZ, USA). 
3.1.5. 3D Visualization 
The primary interactions between the PDE4B and the best hit compounds were demonstrated by 
using Schrodinger Suite 2013-3 package [24]. The predicted PDE4B ligand complex structures were 
visualized using the PyMol program [28]. Primary interactions between the PDE4b and the best hit 
compounds were demonstrated using the PoseView program [29]. 
3.1.6. Ligand Docking 
The protein structures were prepared using the Protein Preparation Wizard of the Schrodinger Suite 
2013-3 [24] with the default settings. After preprocessing the hydrogen bonding network was 
optimized automatically and water molecules which have a distance of at least 5 Angstrom from hetero 
atoms or have less than 2 H-bonds to non-water atoms were removed. Metals were kept in all 
structures. Coordinates for missing side chain atoms were predicted automatically. The ligand 
structures were prepared with the Ligprep module using the default parameters, except that the 
maximum number of stereoisomers was set to 4. Default parameters were used in all Glide XP, 
Induced Fit Docking and Prime MM-GBSA ΔGbind calculations. 
3.2. Assay Development and Biological Screening 
3.2.1. PDE5A1 
The in vitro biological assay we used is based on PDE5 cleavage of the phosphodiester bond of 
[3H]cGMP resulting in [3H]5'-GMP, which is further converted to [3H]guanosine by snake venom 
nucleotidase. Unreacted cGMP is removed by solid phase extraction using an ion exchange resin. 
[3H]guanosine content of the supernatant is determined by scintillation counting. The obtained signal is 
proportional to the amount of cleaved cGMP. 
As an enzyme source recombinant full length PDE5A1 expressed in baculovirus-Sf9 system was 
used for the assay development. PDE5 inhibitors Dypridamole, Zaprinast and Sildenafil were used to 
validate the assay [19]. 
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3.2.2. PDE4B2 
The in vitro biological assay is almost identical to that we used for PDE5 with the  
significant difference, that the substrate is [3H]cAMP (substrate concentration was 1 µM) instead of 
[3H]cGMP [19]. The recombinant PDE4B2 was used as enzyme source for assay development. The 
full length PDE4B2 gene was cloned based on sequence information deposited in Genbank (Accession 
number: NM_001037339) and the sequence was verified by DNA sequencing. The full length 
PDE4B2 was expressed using a bacolovirus-insect cell expression system. We used Sf9 cell line and 
pVL1393 transfer vector. Recombinant virus infected Sf 9 lysate was used as the enzyme source.  
As a first step the recombinant PDE4B2 was titrated—and the appropriate amount of the cell  
lysate for inhibition experiments was determined. In the second step a known PDE4 inhibitor  
(3,5-dimethyl-1-(3-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester) was used to validate  
the assay. 
For selectivity measurements PDE2A3, PDE3A, PDE4D4, PDE7A1, PDE8B1, PDE9A1, 
PDE10A1 and PDE11A4 were cloned and expressed in Sf9 cells similar to PDE5 and PDE4B2.  
In case of PDE3, PDE7, PDE8 and PDE4D4 the substrate was [3H]cAMP and for PDE2, PDE9, 
PDE10, and PDE11 we used [3H]cGMP as substrate, which were used universally at 1 µM concentration. 
The following known inhibitors were used in the assays: BAY-60-7550 (PDE2), trequinsin 
hydrochloride (PDE3, PDE8), BRL 50481 (PDE7), tadalafil (PDE5, PDE11), BAY-73-6691 (PDE9) 
and papaverine hydrochloride (PDE10). 
4. Conclusions 
In summary 3D shape/flexibility-based similarity search (Screen3D) is a sensitive and fast approach 
to select potentially active compounds [53]. It can be used either independently or in combination with 
2D similarity search (depending on the size of the library). This method is particularly useful for 
refinement of 2D virtually prescreened libraries. Alternatively 2D/3D similarity selection methods can 
be combined. Thus, we proposed and applied a fusion (2D/3D) score and cut-off value. The novel 
fusion score approach led to improved hit rate and identification of novel chemotypes and significantly 
active compounds within known chemotypes. Since T3D is rather chemotype selective the fusion score 
can be applied differently according to individual chemical classes rather than an ultimate score will be 
used. Further refinement and investigation is needed to device a fusion score which is less sensitive to 
structural differences.  
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